PMA device
Orthovisc High Molecular Weight Hyaluronan
Anika Therapeutics, Inc. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Feb 4, 2004, newest Dec 30, 2011Knee osteoarthritis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
33
Naming "Orthovisc High Molecular"
MAUDE reports
0
Brand "Orthovisc High Molecular", since 2015
PubMed studies
0
Mentioning "Orthovisc High Molecular"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Orthovisc High Molecular Weight Hyaluronan
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- ORTHOVISC HIGH MOLECULAR WEIGHT HYALURONANPMA supplement
P030019-S014 · Decided Dec 30, 2011 · 927 days after receipt · Normal 180 Day Track No User Fee
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
- ORTHOVISC HIGH MOLECULAR WEIGHT HYALURONANPMA supplement
P030019-S012 · Decided Nov 8, 2006 · 91 days after receipt · Normal 180 Day Track
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
P030019 · Decided Feb 4, 2004 · 250 days after receipt
Device type: Acid, hyaluronic, intraarticular (MOZ) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Orthovisc High Molecular", any status and sponsor, newest update first.
- Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis PainNot yet recruiting
Hospital Universitari Joan XXIII de Tarragona.Academic, hospital or other
NCT07901374 · 70 participants (planned) · Start Nov 2026 · Primary completion May 2028
Device: Intra-articular Hyaluronic Acid · For: Knee Osteoarthritis; Chronic Knee Pain
Sites: Tarragona, Spain
Amina Fouad FaragAcademic, hospital or other
NCT07932912 · 66 participants · Start Nov 1, 2023 · Primary completion Nov 30, 2024
Device: 0.8% High-Molecular-Weight Hyaluronic Acid Gel · For: Periodontitis
Sites: Giza, Egypt
- Verifying the Effectiveness of the NUsurface® SystemPivotal-lookingCompleted
Phoenix KineticsNot on our public-company list
NCT02108496 · 337 participants · Start Jul 2014 · Primary completion Jun 2021
Device: NUsurface® Meniscus Implant · For: Meniscectomy; Osteoarthritis
Sites: Indianapolis, Indiana; Boston, Massachusetts; Roxbury Crossing, Massachusetts · 9 sites in all
30 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Orthovisc High Molecular", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MOZ
4,975 reports: 669 malfunction, 3,945 injury, 278 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Orthovisc High Molecular"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
- Orthovisc Sodium HyaluronateAnika Therapeutics, Inc. · PMA 2007
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.